Resolving a batch hold and protecting your filing timeline requires more than a “test result”; it requires chemical identification that withstands regulatory scrutiny. Gateway Analytical provides the scientific authority required to resolve these investigations. Our Ph.D.-led team moves beyond standard pass/fail to deliver definitive identification and actionable root-cause insight.

Analytical Workflows for Forensic Investigations

We leverage a specialized suite of instrumentation specifically configured to deliver regulator-ready reports for complex matrices:

• LC-MS/MS & QTOF-MS: We provide precise chemical identification of unknown compounds and characterization of reactive byproducts where standard chromatography fails.
• GC-MS: We pinpoint volatile and semi-volatile extractables, identifying the specific chemical contributors to particulate formation.
• SEM-EDS & Micro-Raman Spectroscopy: We deliver high-resolution morphological and chemical characterization to distinguish between visible and subvisible particles at the source.

Contamination Tracing & Regulatory Defense

A pass/fail result is rarely enough to satisfy a deep-dive BLA review or a Pre-Approval Inspection (PAI). Gateway provides the analytical depth to pinpoint the exact source of a deviation—ensuring your investigation package survives governance and demonstrates a total command of your particulate control strategy.

Do not let an unidentified particle escalate into a prolonged disruption. Trust Gateway Analytical for immediate, expert support. Reach out today for a priority consultation:
(724) 443-1900 | in**@***************al.com

The post Forensic Particulate Investigations: Navigating Quality Control Obstacles appeared first on Analysis Solutions.

Our Unified Approach to Drug Delivery & Analytical Defensibility

We were proud to showcase how combining advanced elastomeric closure components with robust analytical strategies strengthens both product performance and regulatory confidence alongside our parent company Aptar Pharma. Throughout the week, discussions centered on how developers can proactively address particulate and CCI risks across increasingly complex delivery systems.

Key focus areas included:

Visible Particulate Characterization

Attendees explored investigative workflows for identifying unknown particulates using SEM-EDS and micro-Raman — crucial for batch-release confidence and for resolving high-risk events.

Subvisible Particle Testing for Emerging Modalities

Teams working with biologics, LNPs, CGT products, and mRNA therapies engaged in deep discussions on low-volume method verification, USP <788>/<787> strategies, and establishing scientifically appropriate bridges for new modalities.

Container Closure Integrity (CCI) Strategies for Complex Systems

With delivery platforms evolving rapidly, visitors were eager to learn how CCI testing integrates into system-level optimization and long-term risk mitigation.

Technology Lab Demonstrations: A Hands-On Look at Advanced Tools

Our live Technology Lab sessions, delivered in partnership with Lighthouse Instruments and PTI, provided attendees with a firsthand look at the CCI and inspection technologies shaping the next generation of compliant, cGMP-aligned testing strategies.

These demonstrations highlighted how leading developers leverage these tools to:

· Improve detection sensitivity for DIPs (Difficult-to-Inspect Products)

· Strengthen risk-based particulate and CCI assessments

· Replace operator-dependent inspection steps with instrument-driven confidence

· Generate defensible data packages that align with tightening global expectations

Themes That Defined PDA Week 2026

Across hundreds of conversations, several themes stood out:

· Regulatory expectations are accelerating faster than ever

· Scientific defensibility, not minimum compliance, is the new standard

· Complex modalities demand new approaches to particulate and CCI challenges

· Integrated device–analytics strategies are essential for de-risking development

We appreciated every opportunity to help teams think through next-steps for their 2026 programs.

Let’s Continue the Conversation

Thank you to everyone who visited us in Denver, whether at the booth, the Technology Lab, or in one of the conference sessions. We look forward to building on the connections made throughout the week.

If you were unable to attend, or if you’d like to continue discussing your particulate or CCI strategy:

in**@***************al.com (724) 443-1900

Now is the ideal time to prepare your analytical roadmap for 2026.

Gateway Analytical — Scientific Clarity for Complex Problems.

The post PDA Week 2026 Recap: Advancing Particulate Science, CCI Strategy, and Regulatory Readiness appeared first on Analysis Solutions.

We’re here live at PDA Week 2026 in Denver, where global leaders in sterile manufacturing, quality, and regulatory science are exploring the technologies and analytical strategies shaping the future of injectable product safety. If you’re attending, make sure to stop by booth 204 to connect with the team from Gateway Analytical. As the regulatory landscape tightens and expectations for data defensibility grow, this year’s meeting offers an unparalleled opportunity to sharpen your technical expertise in visible particulates, subvisible particle testing, and Container Closure Integrity (CCI).

Throughout the week, our experts are leading discussions on how development teams can prepare for emerging expectations in 2026 and beyond. Whether evaluating DIP (Difficult-to-Inspect Product) strategies or building scientific bridges for complex modalities, our team is here to help attendees:

· Strengthen particulate and CCI readiness

· Build scientifically defensible data packages

· Navigate evolving USP and global regulatory standards

· Resolve particulate “unknowns” with forensic precision

· Optimize inspection strategies for challenging delivery systems

Stop by Booth 204 to explore how our analytical workflows support confident, compliant decision-making across the product lifecycle.

Experience the Technology Lab — Live at Booth 204

Don’t miss the opportunity to see advanced instrumentation from our partners Lighthouse Instruments and PTI in action. These live demonstrations show how cutting-edge CCI and inspection technologies integrate directly into cGMP-aligned testing strategies, enabling teams to:

· Detect and address closure performance issues

· Support risk-based particulate and CCI analysis

· Improve detection sensitivity for DIPs and novel modalities

· Generate higher-quality, defensible analytical data

If you want to experience best-in-class tools used by leading global developers, the Technology Lab is a must-see.

Let’s Connect While You’re Here

Before you leave the exhibit hall, make sure you have a clear plan for your next analytical milestone. Our team is available onsite for:

· Private strategy sessions

· Method Verification Gap Checks

· Particulate testing roadmap reviews

· CCI strategy consultations

We look forward to collaborating with you here in Denver at Booth 204!

Gateway Analytical — Scientific Clarity for Complex Problems.

The post Live at PDA Week 2026: Visit Gateway Analytical at the Aptar Pharma Exhibit appeared first on Analysis Solutions.

Gateway Analytical is proud to attend the 2026 PDA Annual Meeting Week in Denver, Colorado alongside our parent company, Aptar Pharma. Together, we will highlight how integrated device components and analytically robust data packages create a solid foundation for safe, compliant, and innovative drug products.

As regulatory expectations evolve, development and QC teams face growing demands for defensible particulate and CCI data, especially when working with new modalities, novel delivery systems, and Difficult-to-Inspect Products (DIPs). Ensuring your analytical strategy is built to withstand intensified scrutiny is essential for success in 2026 and beyond.

Bridging Device Innovation and Analytical Defensibility

From early development through commercial deployment, regulatory expectations surrounding particulate control and container closure performance continue to increase. During PDA Week, our team will focus on how to strengthen strategies in key risk areas:

Visible Particulate Characterization

Through advanced forensic techniques, including SEM-EDS and micro-Raman spectroscopy, we help teams investigate, identify, and resolve particulate “unknowns” that could otherwise lead to batch holds or release delays.

Subvisible Particle Testing & Scientific Bridging

As CGT, LNP, and mRNA therapies introduce new challenges, low-volume method verification and scientifically appropriate bridging strategies become essential. Our approach preserves precious API while generating high-quality, defensible data.

Container Closure Integrity (CCI) Testing

Ensuring functional suitability across the full container-closure-delivery system is critical for regulatory approval. We support teams in evaluating closure performance using cGMP-aligned CCI technologies and risk-based methodologies.

Unified Solutions for Complex Modalities

Our combined expertise—spanning analytical chemistry, materials science, and elastomeric component engineering—equips drug developers with actionable solutions for:

· System-Level Optimization: Evaluating device and closure interactions in real-world patient environments.

· Complex Modality Testing: Tailored workflows for CGT, LNP, and mRNA programs requiring low-volume and high-sensitivity analytical methods.

· Forensic Root-Cause Resolution: Rapid identification of particulate contaminants to turn a batch hold into a defensible path forward.

See Our Technology Lab at PDA Week

Don’t miss your opportunity to experience live instrument demonstrations featuring industry-leading tools from Lighthouse Instruments and PTI. These technologies form the backbone of robust CCI and particulate-inspection strategies adopted by leading pharma and biotech companies worldwide.

Whether you’re refining a USP <788>/<787> testing strategy, building a DIP-resilient inspection approach, or preparing for regulatory submission, our team is ready to help you accelerate your readiness.

Connect With Us in Denver – PDA WEEK – DENVER, CO – MARCH 2026

Don’t wait for an inspection to find a gap in your analytical strategy. Start preparing for your 2026 analytical strategy today.

Gateway Analytical — Scientific Clarity for Complex Problems.

The post Gateway Analytical and Aptar Pharma Prepare to Showcase Integrated Drug Delivery & Analytical Solutions at PDA Week 2026 appeared first on Analysis Solutions.

This year’s program carries special significance as the PDA celebrates its 80th anniversary in the United States and 20th anniversary in Europe — a testament to decades of scientific collaboration and advancement. We are proud to be part of this milestone event and contribute to the conversations shaping the future of injectable product quality.

What We’re Focusing on at PDA Week 2026

As regulatory expectations continue to evolve, development teams face growing pressure to generate scientifically defensible data for complex modalities, newer delivery systems, and Difficult-to-Inspect Products (DIPs). Throughout the week, our team will be discussing analytical strategies that help programs anticipate and overcome these challenges, including:

Visible Particulate Characterization

Identifying and understanding visible particles remains a top regulatory concern. We’ll explore forensic approaches, including SEM-EDS and micro-Raman, that support root-cause investigations and help teams resolve particulate events before they escalate.

Subvisible Particle Testing

From monoclonal antibodies to LNP and mRNA platforms, subvisible particle control is a critical component of product safety. Our team will highlight best practices for USP <788>/<787> testing, low-volume verification, and scientific bridging strategies for emerging modalities.

Container Closure Integrity (CCI) Testing

With delivery systems growing more complex, ensuring closure performance is essential. We’ll showcase how robust CCI testing integrates with particulate strategies to reduce risk across the product lifecycle.

Why Meet with Gateway Analytical in Denver?

PDA Week offers the unique opportunity to engage directly with industry experts and troubleshoot real-world analytical challenges. Whether your focus is regulatory submission preparation, method verification, particulate troubleshooting, or evaluating DIP scenarios, our scientists are ready to support your 2026 roadmap.

Attendees can gain insights into:

· Navigating evolving USP and global regulatory expectations

· Building defensible particulate and CCI testing strategies

· Addressing low-availability sample concerns for new modalities

· Strengthening method verification and system suitability

· Reducing risk and supporting faster, more confident decision-making

Connect With Us at PDA Week 2026 – MARCH 22-25

If you’ll be in Denver, we’d welcome the chance to meet for a strategy session or a 1-on-1 discussion tailored to your analytical challenges and development goals.

To schedule a meeting, please contact us at in**@***************al.com or call (724) 443-1900.

Gateway Analytical — Scientific Clarity for Complex Problems.

The post Gateway Analytical Prepares for PDA Week 2026: Let’s Talk Particulates, CCI, and 2026 Regulatory Readiness! appeared first on Analysis Solutions.

Gateway Analytical provides the scientific authority required to resolve these investigations. Our Ph.D.-led team uses advanced chromatography and microscopy to provide definitive identification and root-cause insight.

Analytical Workflows for Particulate Investigations: We leverage a specialized suite of instrumentation to deliver regulator-ready reports:

LC-MS/MS & QTOF-MS: Utilized for the chemical identification of unknown compounds and characterization of reactive byproducts.

GC-MS: Utilized to identify volatile and semi-volatile extractables contributing to particulate formation.

SEM-EDS & Micro-Raman Spectroscopy: Utilized for the morphological and chemical characterization of both visible and subvisible particles.

Contamination Tracing: We provide the analytical depth to pinpoint the source of the deviation, ensuring your data survives governance and inspection.

Do not let an unidentified particle escalate into a prolonged disruption. Trust Gateway for immediate, expert support. Reach out today for a priority consultation:
(724) 443-1900 | in**@***************al.com

The post Forensic Particulate Investigations: Navigating Quality Control Obstacles appeared first on Analysis Solutions.

When dealing with suspensions, amber vials, or cell therapies, your control strategy must prove the inspection process can actually detect intended risks. Gateway Analytical provides the secondary verification required to close this compliance gap:

Sensitivity Verification: Utilizing Secondary Destructive Visible Particulate Screening to quantify detection limits.

Scientific Justification: Providing the data-driven rationale for your AQL performance in non-standard modalities.

Audit-Ready Documentation: Delivering a defensible technical package that proves your inspection process meets USP <1790> expectations.

Ready to fast-track your E&L investigations? Reach out today for a priority consultation with our team:
(724) 443-1900 | in**@***************al.com

The post Closing the USP <1790> Gap: Demonstrating Inspection Adequacy for DIPs appeared first on Analysis Solutions.

Every month, we’ll bring you the latest on evolving regulatory expectations, upcoming industry events, and key insights to keep your projects & drug products on track. We are your go-to resource for analytical testing tools, and specialized consulting, designed to make sure you stay ahead of the curve.

Beyond Compliance: The Defensibility Gap in Subvisible Particle Testing

In the evolving regulatory climate of 2026, regulators are looking beyond simple pass/fail metrics toward the scientific justification and data supporting drug product safety. For complex drug products, such as high-concentration proteins or viral vectors, standard testing settings may not provide a complete picture of your particulate population.

Getting Ahead of the Curve: Closing the Gap Before the Audit

Many organizations still rely on outdated method suitability data that was generated during early-phase development, data that often lacks the rigor required for a commercial filing in 2026.

Method Verification Gap Check & Strategy Review

Our Method Verification Gap Check & Strategy Review is a 30-minute high-level review designed to identify vulnerabilities in your subvisible & visible particle data package. We evaluate your current protocols and operations against evolving regulatory expectations to ensure that when the PAI (Pre-Approval Inspection) occurs, your data is already defensible.

Choose an expert from Gateway Analytical to conduct your drug product Strategy Review. See how our team can help operationalize and optimize your drug product!

Advanced Therapies Week 2026 – Join Our Director of Sales & Marketing!

Shaping the Future of Advanced Therapies

Join our Director of Sales and Marketing at the San Diego Convention Center, February 9–12, 2026, to get connected with our team and learn more about the cell and gene therapy ecosystem. We look forward to discussing how Gateway Analytical can support your journey from R&D to clinical success through specialized particulate analysis and method verification tailored to the needs of your most complex drug products!

This event is a critical hub for the cell and gene therapy community, focusing on the commercialization and manufacturing scale-up of next-generation medicines. We look forward to discussing how Gateway Analytical can support your journey from R&D to clinical success through specialized particulate analysis and method verification.

Looking Forward to 2026 and Beyond with Gateway Analytical..

From shifting regulatory landscapes to the industry’s biggest events, we provide the analytical tools and specialized consulting you need to keep your projects moving forward. Let’s stay ahead of the curve, together.

Reach out today for a priority consultation: (724) 443-1900 | in**@***************al.com

The post The Gateway Analytical Journal – Monthly Roundtable – Issue 01 // January 2026 appeared first on Analysis Solutions.

At Gateway Analytical, container integrity and particulate control are treated as governance-led strategies. We focus on the intersection of formulation complexity, primary container behavior, and inspection limitations to ensure that the container closure system strengthens the regulatory narrative rather than introducing residual risk.

As we move into 2026, we are excited to partner with your biotech, pharmaceutical, and quality-driven CDMO team to deliver:

Proactive System Qualification
Applying USP <661.1> and <661.2> to establish an early, high-resolution understanding of material safety, compatibility, and extractables control, particularly for non-standard formulations and high-risk modalities.

Deterministic CCIT
Embedding high-sensitivity, deterministic leak detection early in development to replace probabilistic assumptions with quantitative assurance. Reducing downstream investigation burden, and accelerating development and timelines.

System-Level Functional and Inspection
Executing USP <382> suitability testing alongside difficult-to-inspect product strategies to ensure that parenteral, inhalation, and ophthalmic delivery systems perform reliably, not only in the lab, but in real-world patient use and under inspection challenge.

Are you confident your container integrity and particulate data will stand up under inspection? Reach out today for a priority consultation: (724) 443-1900 | in**@***************al.com

The post Beyond Compliance: Navigating the Future of USP <382> and <661> appeared first on Analysis Solutions.

In our recent webinar, we discussed how critical it is to evaluate your packaging systems under the new standard. Now that the deadline has passed, the focus shifts to demonstrating active compliance and addressing any remaining gaps.

Key Points Moving Forward:
• System-level functional testing is now mandatory
• Deterministic CCIT is required for sterility assurance and regulatory success

Missed the Webinar? Access Here

With the USP <382> deadline behind us, Gateway Analytical will continue to support pharmaceutical teams in:
• Completing post-deadline gap assessments
• Implementing deterministic CCIT programs
• Executing system-level functional suitability testing
• Preparing regulatory-ready technical documentation

Stay ahead of compliance challenges. Trust the experts at Gateway Analytical to guide your compliance strategy. Our team bridges regulatory and technical gaps through system-level analytical testing, USP <382> functional suitability assessments, and deterministic CCIT programs. Contact our team anytime via phone at (724) 443-1900 or send us an email at in**@***************al.com.

The post USP <382> Is Now in Effect. Here’s What Your Team Needs to Do Next. appeared first on Analysis Solutions.